-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KITE-718 in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KITE-718 in Burkitt Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KITE-718 in Burkitt Lymphoma Drug Details: KITE-718 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naptumomab Estafenatox in Non-Small Cell Lung Cancer Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naptumomab Estafenatox in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JANX-008 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Metastatic Colorectal Cancer Drug Details: JANX-008 is under...
-
Product Insights
Ureter Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Ureter Cancer - Drugs In Development, 2023’, provides an overview of the Ureter Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urethral Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Urethral Cancer - Drugs In Development, 2023’, provides an overview of the Urethral Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urethral Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...